Lacosamide Aristo

Lacosamide, the active ingredient in Lacosamide Aristo, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated as adjunctive therapy for partial‑onset seizures, with or without secondary generalisation, in patients with epilepsy.

GNH USA supplies Lacosamide Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards, is distributed under strict regulatory compliance, and our supply chain ensures consistent availability to support clinical needs across diverse healthcare settings.

Lacosamide is used in the management of epilepsy, targeting partial‑onset seizure activity.

- Partial‑onset seizures (with or without secondary generalisation): provides adjunctive seizure control when added to existing antiepileptic therapy. - Refractory epilepsy: improves overall seizure frequency as part of combination treatment in patients not fully controlled by other agents. - Adjunctive therapy in epilepsy: contributes to better seizure management alongside standard antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Respiratory depression - Hypersensitivity reactions including anaphylaxis - Blood dyscrasias such as agranulocytosis

When prescribing Lacosamide, clinicians should consider several safety factors.

- Pregnancy: Category C – weigh potential benefits against risks and consult obstetric guidance. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function and consider dose modification. - Concomitant antiepileptics: assess for additive CNS effects. - Driving or operating machinery: advise patients about possible dizziness or visual disturbances. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampin): may markedly reduce lacosamide plasma concentrations. - Co‑administration with other agents that prolong PR interval (e.g., class IA anti‑arrhythmics): increases risk of cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): can raise lacosamide levels. - Alcohol: may enhance central nervous system depression. - Other CNS depressants (e.g., benzodiazepines, opioids): monitor for excessive sedation or respiratory effects.